Pulmonary function outcomes for assessing cystic fibrosis care
Jeffrey S Wagener1, Eric P Elkin2, David J Pasta2
1University of Colorado Denver School of Medicine, Aurora, CO, United States.
Summary
Choosing the right measure for cystic fibrosis (CF) patient care is key. Annual FEV(1) is a reliable outcome measure, reflecting practice patterns effectively for CF quality assessment.
Area of Science:
- Pulmonary Medicine
- Clinical Quality Measurement
- Epidemiology
Background:
- Assessing cystic fibrosis (CF) patient quality of care necessitates selecting appropriate outcome measures.
- Pulmonary function outcomes are critical indicators that may reflect clinical practice patterns in CF care.
Purpose of the Study:
- To systematically evaluate pulmonary function outcomes as potential measures of clinical practice patterns in cystic fibrosis care.
- To assess the association between CF care site rankings and practice patterns, including follow-up pulmonary function.
Main Methods:
- Utilized data from the Epidemiologic Study of Cystic Fibrosis.
- Evaluated six pulmonary function outcome variables: best FVC, FEV(1), FEF(25-75) in 2002, and the rate of decline for each from 2000-2002.
- Ranked CF care sites based on these outcome measures and analyzed associations with practice patterns and follow-up pulmonary function.
Main Results:
- CF care sites in the top quartile demonstrated more frequent patient monitoring, treatment of exacerbations, and utilization of chronic therapies and oral corticosteroids.
- The rate of pulmonary function decline in follow-up was not significantly predicted by the initial site ranking.
Conclusions:
- Different pulmonary function outcome measures show slight variations in their association with clinical practice patterns.
- Annual FEV(1) is identified as a robust and effective measure, comparable to other outcomes for assessing CF care quality.
- Current site rankings offer only moderate predictive value for future performance rankings.
Related Concept Videos
Cystic Fibrosis: Management
656
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
656
Pulmonary Function Tests
1.1K
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
1.1K
Cystic Fibrosis: Pathogenesis
1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.4K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.4K
Chronic Obstructive Pulmonary Disease-I: Introduction
4.3K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.3K
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
21
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
21


